Results 171 to 180 of about 493,465 (339)

Perinatal Exposure to the Neonicotinoid Thiacloprid Impacts Transcription of Neuroplasticity and Neuroendocrine Markers in Mice but Not in the Zebrafish Model

Journal of Applied Toxicology, Volume 46, Issue 1, Page 179-197, January 2026.
ABSTRACT Neonicotinoids are widely used insecticides in agriculture, aquaculture, pet care, and urban pest control. Initially developed to selectively target the insect cholinergic system, their extensive use has raised concerns about adverse effects on nontarget vertebrates.
Kirthana Kunikullaya U, Zuzanna M. Baran, Pascal Coumailleau, Laetitia Guillot, Harry W. M. Steinbusch, Fatima Smagulova, Thierry D. Charlier   +6 more
wiley   +1 more source

Mapping the Agonist Binding Site of the Nicotinic Acetylcholine Receptor [PDF]

, 2000
Deirdre Sullivan, Jonathan B. Cohen
openalex   +1 more source

Effectiveness of Psychosocial Interventions for Adults With Substance Use Disorder That Have a Co‐Occurring Common Mental Health Disorder: An Umbrella Review

Drug and Alcohol Review, Volume 45, Issue 1, January 2026.
ABSTRACT Issues People with substance use disorders can have co‐occurring mental disorders. Approach An umbrella review was conducted to identify evidence of the effectiveness of psychosocial interventions for adults (aged 18+) with substance use disorders and co‐occurring common mental health disorders.
Emma L. Simpson, Munira Essat, Ruth Wong, Sarah Stacey, Edward Day   +4 more
wiley   +1 more source

Insect nicotinic acetylcholine receptor agonists as flea adulticides in small animals [PDF]

, 2010
Duc Vo, Walter H. Hsu, Ehab A. Abu‐Basha, Richard J. Martin   +3 more
openalex   +1 more source

Increased Nicotinic Acetylcholine Receptor Protein Underlies Chronic Nicotine-Induced Up-Regulation of Nicotinic Agonist Binding Sites in Mouse Brain

Journal of Pharmacology and Experimental Therapeutics, 2011
M. Marks, Tristan D. McClure-Begley, P. Whiteaker, O. Salminen, Robert W. B. Brown, J. Cooper, A. C. Collins, J. Lindstrom   +7 more
semanticscholar   +1 more source

Relative efficacy of GLP‐1 and GLP‐1/GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 137-150, January 2026.
Abstract Aims There is growing evidence that the GLP‐1 system is implicated in alcohol and other substance use disorders, and that GLP‐1‐based therapies may have therapeutic relevance in alcohol use disorder (AUD). We aimed to determine the impact of GLP‐1 based therapies on incident AUDs in a real‐world setting in patients with T2D.
Alex E. Henney, David R. Riley, Megan Heague, Carl A. Roberts, Theresa J. Hydes, Matthew Anson, David M. Hughes, Uazman Alam, Daniel J. Cuthbertson   +8 more
wiley   +1 more source

Effects of a nicotinic agonist on the Brief Psychiatric Rating Scale five-factor subscale model in schizophrenia. [PDF]

Schizophr Res, 2018
Lewis AS, Olincy A, Buchanan RW, Kem WR, Picciotto MR, Freedman R.   +5 more
europepmc   +1 more source

The Unique α4(+)/(−)α4 Agonist Binding Site in (α4)3(β2)2 Subtype Nicotinic Acetylcholine Receptors Permits Differential Agonist Desensitization Pharmacology versus the (α4)2(β2)3 Subtype

Journal of Pharmacology and Experimental Therapeutics, 2014
J. Eaton, L. Lucero, Harrison J. Stratton, Yongchang Chang, John F. Cooper, Jon M. Lindstrom, Ronald J. Lukas, P. Whiteaker   +7 more
semanticscholar   +1 more source

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 337-346, January 2026.
Abstract Aims Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report
Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men

, 2007
Ann Olincy, Karen E. Stevens
openalex   +1 more source